188 related articles for article (PubMed ID: 24482413)
1. Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
Shoji H; Morizane C; Hiraoka N; Kondo S; Ueno H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
Jpn J Clin Oncol; 2014 Apr; 44(4):324-30. PubMed ID: 24482413
[TBL] [Abstract][Full Text] [Related]
2. Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater.
Kim HS; Shin SJ; Kim JH; Kim H; Choi HJ
Tohoku J Exp Med; 2013 Sep; 231(1):21-8. PubMed ID: 23994910
[TBL] [Abstract][Full Text] [Related]
3. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
Ecker BL; Vollmer CM; Behrman SW; Allegrini V; Aversa J; Ball CG; Barrows CE; Berger AC; Cagigas MN; Christein JD; Dixon E; Fisher WE; Freedman-Weiss M; Guzman-Pruneda F; Hollis RH; House MG; Kent TS; Kowalsky SJ; Malleo G; Salem RR; Salvia R; Schmidt CR; Seykora TF; Zheng R; Zureikat AH; Dickson PV
JAMA Surg; 2019 Aug; 154(8):706-714. PubMed ID: 31141112
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
Overman MJ; Varadhachary GR; Kopetz S; Adinin R; Lin E; Morris JS; Eng C; Abbruzzese JL; Wolff RA
J Clin Oncol; 2009 Jun; 27(16):2598-603. PubMed ID: 19164203
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
Kim ST; Lee J; Lee KT; Lee JK; Lee KH; Choi SH; Heo JS; Choi DW; Park SH; Park JO; Lim HY; Park YS; Kang WK
Med Oncol; 2010 Dec; 27(4):1149-54. PubMed ID: 19898973
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Jin Z; Hartgers ML; Sanhueza CT; Shubert CR; Alberts SR; Truty MJ; Muppa P; Nagorney DM; Smyrk TC; Hassan M; Mahipal A
Eur J Surg Oncol; 2018 May; 44(5):677-683. PubMed ID: 29506768
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.
Gulhati P; Raghav K; Shroff RT; Varadhachary GR; Kopetz S; Javle M; Qiao W; Wang H; Morris J; Wolff RA; Overman MJ
Cancer; 2017 May; 123(6):1011-1017. PubMed ID: 27859010
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
Moekotte AL; Malleo G; van Roessel S; Bonds M; Halimi A; Zarantonello L; Napoli N; Dreyer SB; Wellner UF; Bolm L; Mavroeidis VK; Robinson S; Khalil K; Ferraro D; Mortimer MC; Harris S; Al-Sarireh B; Fusai GK; Roberts KJ; Fontana M; White SA; Soonawalla Z; Jamieson NB; Boggi U; Alseidi A; Shablak A; Wilmink JW; Primrose JN; Salvia R; Bassi C; Besselink MG; Abu Hilal M
Br J Surg; 2020 Aug; 107(9):1171-1182. PubMed ID: 32259295
[TBL] [Abstract][Full Text] [Related]
10. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Neoptolemos JP; Moore MJ; Cox TF; Valle JW; Palmer DH; McDonald AC; Carter R; Tebbutt NC; Dervenis C; Smith D; Glimelius B; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Ghaneh P; Halloran CM; Lerch MM; Oláh A; Rawcliffe CL; Verbeke CS; Campbell F; Büchler MW;
JAMA; 2012 Jul; 308(2):147-56. PubMed ID: 22782416
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater.
Sohn BS; Yuh YJ; Kim KH; Jeon TJ; Kim NS; Kim SR
Tumori; 2013; 99(2):139-44. PubMed ID: 23748804
[TBL] [Abstract][Full Text] [Related]
12. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Takayoshi K; Kusaba H; Uenomachi M; Mitsugi K; Makiyama C; Makiyama A; Uchino K; Shirakawa T; Shibata Y; Shinohara Y; Inadomi K; Tsuchihashi K; Arita S; Ariyama H; Esaki T; Akashi K; Baba E
Cancer Chemother Pharmacol; 2017 Aug; 80(2):333-342. PubMed ID: 28653251
[TBL] [Abstract][Full Text] [Related]
13. Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma.
Okano K; Oshima M; Yachida S; Kushida Y; Kato K; Kamada H; Wato M; Nishihira T; Fukuda Y; Maeba T; Inoue H; Masaki T; Suzuki Y
J Surg Oncol; 2014 Aug; 110(2):156-62. PubMed ID: 24619853
[TBL] [Abstract][Full Text] [Related]
14. Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
Prescrire Int; 2013 May; 22(138):122. PubMed ID: 23819172
[TBL] [Abstract][Full Text] [Related]
15. Adenocarcinoma of the ampulla of Vater: what treatment options are available?
Senatore FJ; Ynson ML; Dasanu CA
J Oncol Pharm Pract; 2015 Oct; 21(5):364-9. PubMed ID: 24906539
[TBL] [Abstract][Full Text] [Related]
16. Tumors of the ampulla of vater: histopathologic classification and predictors of survival.
Carter JT; Grenert JP; Rubenstein L; Stewart L; Way LW
J Am Coll Surg; 2008 Aug; 207(2):210-8. PubMed ID: 18656049
[TBL] [Abstract][Full Text] [Related]
17. Expression of Bcl-2 19-kDa interacting protein 3 predicts prognosis after ampullary carcinoma resection.
Fujimoto T; Ohtsuka T; Date K; Kimura H; Matsunaga T; Mori Y; Miyasaka Y; Mochidome N; Oda Y; Nakamura M
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):489-96. PubMed ID: 27273680
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy.
Jiang ZQ; Varadhachary G; Wang X; Kopetz S; Lee JE; Wang H; Shroff R; Katz M; Wolff RA; Fleming J; Overman MJ
Ann Oncol; 2013 Sep; 24(9):2349-53. PubMed ID: 23704197
[TBL] [Abstract][Full Text] [Related]
19. Differentiation and prognostic markers in ampullary cancer: Role of p53, MDM2, CDX2, mucins and cytokeratins.
Perysinakis I; Minaidou E; Mantas D; Sotiropoulos GC; Leontara V; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Pathol Res Pract; 2016 Nov; 212(11):1039-1047. PubMed ID: 27688085
[TBL] [Abstract][Full Text] [Related]
20. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.
Perysinakis I; Minaidou E; Leontara V; Mantas D; Sotiropoulos GC; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Int J Surg Pathol; 2017 Feb; 25(1):31-40. PubMed ID: 27543509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]